5-FU PGX

"Prevalence of various genetic and epigenetic changes in genes associated with the anti-cancer drug 5-FU metabolism in patients with severe toxicity, healthy donors and various Israeli populations."

Coordinatore	PRONTO DIAGNOSTICS LTD    more  Organization address address: OPENHEIMER STREET 5 SCIENCE PARK city: REHOVOT postcode: 76701 contact info Titolo: Dr. Nome: Nir Cognome: Navot Email: send email Telefono: -9315208 Fax: -9315209
Nazionalità Coordinatore	Israel [IL]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IRG-2008
Funding Scheme	MC-IRG
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-10-01   -   2012-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	PRONTO DIAGNOSTICS LTD  Organization address address: OPENHEIMER STREET 5 SCIENCE PARK city: REHOVOT postcode: 76701 contact info Titolo: Dr. Nome: Nir Cognome: Navot Email: send email Telefono: -9315208 Fax: -9315209	IL (REHOVOT)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'5-Fluorouracil (5-FU) has been one of the most commonly used drugs in the treatment of various types of cancer (in particular, colorectal and breast) for the past fifty years. 5-FU is a drug for which genetic and epigenetic variation in the drug-metabolizing enzyme (dihydropyrimidine dehydrogenase [DPD]) and the drug target enzyme (thymidyalate synthase [TS]) can influence both toxicity and response to treatment. Through a comprehensive investigation and screening of various genetic (SNPs, deletions, insertions and duplications) and epigenetic (methylation in the promoter region) variations in the six major genes (DPYD, DHP, BUP, TP, OPRT and TS) encoding 5-FU metabolizing enzymes, we intend to identify the spectrum of molecular alterations associated with a patient’s response to the drug. We will then measure the frequency of known and newly observed mutations in patients with adverse side effects, healthy volunteers and various Israeli populations. The following step will be to establish a set of mutations that is likely to more fully elucidate the causes that impact the toxicity and efficacy of 5-FU. Finally, we will translate our research findings into a genetic testing tool for use prior to cancer treatment, thus integrating Pharmacogenetics into health care practice.'